A Phase II Trial on Osimertinib as a First-Line Treatment for EGFR Mutation-Positive Advanced NSCLC in Elderly Patients: The SPIRAL-0 Study
Details
The content you want is available to Zendy users.Already have an account? Click here. to sign in.
Details